XML 18 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Feb. 28, 2011
Jun. 19, 2011
United Therapeutics Corporation [Member]
Licensing Agreements [Member]
Jun. 30, 2012
United Therapeutics Corporation [Member]
Licensing Agreements [Member]
Jun. 30, 2012
Stock Options and Shares Employees [Member]
Jun. 30, 2012
Stock Options and Shares Directors and Officers [Member]
Jun. 30, 2012
Restricted Shares and Restricted Share Units [Member]
Jun. 30, 2011
Restricted Shares and Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                    
Forfeiture rate                             5.00% 0.00%    
Granted, weighted-average grant date fair value                                 $ 2.54 $ 1.91
Grants received $ 9,412       $ 6,256       $ 9,412 $ 6,256   $ 244            
Severance expense                 275 225 134              
Derivative fair value asset (liability) (138)       7       (138) 7                
Revenue [Line Items]                                    
Contingent consideration receivable if certain regulatory milestones are reached                         37,500          
Deferred revenue for intangible asset                           5,000        
Deferred revenue recognition period for intangible asset                           6 years 6 months        
Revenues 101 230 231 154             716           716        
Advance payment for development costs                         2,000          
Research and development expenses                 $ 12,706 $ 8,311 $ 6,123     $ 424